Grifols, S.A. (GRF.MC)
- Previous Close
8.62 - Open
8.45 - Bid 8.39 x --
- Ask 8.40 x --
- Day's Range
8.22 - 8.48 - 52 Week Range
6.36 - 15.92 - Volume
3,310,556 - Avg. Volume
4,255,930 - Market Cap (intraday)
5.054B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
92.73 - EPS (TTM)
0.09 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 3, 2021
- 1y Target Est
18.71
Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain.
www.grifols.com23,744
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GRF.MC
Performance Overview: GRF.MC
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRF.MC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRF.MC
Valuation Measures
Market Cap
5.22B
Enterprise Value
15.47B
Trailing P/E
95.76
Forward P/E
21.01
PEG Ratio (5yr expected)
0.37
Price/Sales (ttm)
0.89
Price/Book (mrq)
1.00
Enterprise Value/Revenue
2.35
Enterprise Value/EBITDA
13.09
Financial Highlights
Profitability and Income Statement
Profit Margin
0.90%
Return on Assets (ttm)
2.14%
Return on Equity (ttm)
2.20%
Revenue (ttm)
6.59B
Net Income Avi to Common (ttm)
59.31M
Diluted EPS (ttm)
0.09
Balance Sheet and Cash Flow
Total Cash (mrq)
646.04M
Total Debt/Equity (mrq)
133.58%
Levered Free Cash Flow (ttm)
-1.26B